Pfizer Inc (PFE)

$25.01 +0.10 (0.40%)
Market Cap 142.54B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.14
Forward PE 8.43
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 45,080,100
Avg Vol 42,153,613
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 54%
Beta 0.35
Analysts Sell
Price Target $28.70

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Toptradersam
Toptradersam Aug. 3 at 9:05 AM
$NBIS $BMY $PFE $NVO $ALAR 🚀 Hunting for the next big winner? Check out why this stock has my attention. Watch the full breakdown! 📈 https://www.youtube.com/watch?v=ZgFvSFCwFfE
0 · Reply
Etiqute
Etiqute Aug. 3 at 8:35 AM
$PFE 💡 Strategic TakeawayWhen higher volume drives the price upward (as seen on Friday) and lower volume occurs on down days (as seen on Wednesday), it implies institutional accumulation rather than panic selling. This dynamic is a healthy short-term sign, though Wall Street consensus remains a conservative Hold due to broader post-COVID revenue transitions and patent cliffs. High-risk single-equity exposures like this should always be positioned within a diversified portfolio to protect against sudden capital losses.
0 · Reply
Etiqute
Etiqute Aug. 3 at 8:33 AM
$PFE Volume and Price BreakdownEvaluating volume behavior alongside daily price action reveals the underlying market sentiment:Friday, July 31 (Bullish Volume): Trading volume rose to 45.08 million shares, comfortably exceeding the stock's 36.75 million average. This heavy volume accompanied a green day where the stock closed higher at $25.01, demonstrating strong buying pressure to wrap up the week.Thursday, July 30 (Bearish Volume): Volume remained high at 44.95 million shares, but the stock faced minor selling pressure, sliding slightly from its open to close at $24.91.WEDNESDAY, July 29 (Weak Bearish Volume): The stock dropped from an opening price of $25.35 to close at $25.15. Crucially, this sell-off happened on lower-than-average volume of 30.39 million shares, signaling that sellers lacked aggressive conviction.
0 · Reply
Etiqute
Etiqute Aug. 3 at 8:32 AM
$PFE Pfizer’s (PFE) stock trading volume over the last three trading days shows a moderately bullish shift in short-term volume accumulation. Despite some mixed daily price action, the volume notably expanded on days with positive price movement.
0 · Reply
Rmccall
Rmccall Aug. 3 at 4:06 AM
$PFE I own this but now loading up on $SLS diamdin in the rough
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 3 at 12:37 AM
$BMY looking great just like $PFE $GILD and of course the venerable $JNJ ⭐️ ⭐️ ⭐️ ⭐️
0 · Reply
Balancedbearizback
Balancedbearizback Aug. 2 at 11:58 PM
$PFE cancer free and rock hard
0 · Reply
CrispDry
CrispDry Aug. 2 at 10:27 PM
$ABVX just give us that $PFE or $SNY bomba tonight. I need to clear the drama and suspense
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 2 at 8:59 PM
$IGC https://youtu.be/gDDhi_U0ZWQ?is=_PgNotWj9U3p8bLY Easy money!! Why not invest and take a chance $MRNA $PFE Ram Mukunda continues to show strong, steady leadership—clear communication, disciplined execution, respected partnerships, and a sharp focus on solving major unmet needs in Alzheimer’s. Quiet confidence backed by results.
0 · Reply
reyofhope
reyofhope Aug. 2 at 8:42 PM
$PFE I believe in big Al .
0 · Reply
Latest News on PFE
Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Jul 30, 2026, 7:48 AM EDT - 3 days ago

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Pfizer says LITFULO studies meet co-primary endpoints

2026-07-30T11:03:18.000Z - 3 days ago

Pfizer says LITFULO studies meet co-primary endpoints

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

Jul 30, 2026, 6:45 AM EDT - 3 days ago

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

EC authorizes Pfizer, BioNTech XFG-adapted COVID-19 vaccine in EU

2026-07-29T20:42:19.000Z - 4 days ago

EC authorizes Pfizer, BioNTech XFG-adapted COVID-19 vaccine in EU

BNTX

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Jul 29, 2026, 4:30 PM EDT - 4 days ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

BNTX

Pfizer's prostate cancer drug combination gets US FDA priority review

Jul 22, 2026, 4:48 PM EDT - 11 days ago

Pfizer's prostate cancer drug combination gets US FDA priority review

FDA grants priority review for Pfizer’s Talzena plus Xtandi

2026-07-22T20:40:37.000Z - 11 days ago

FDA grants priority review for Pfizer’s Talzena plus Xtandi

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Jul 22, 2026, 4:30 PM EDT - 11 days ago

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

Jul 21, 2026, 7:10 PM EDT - 12 days ago

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

LLY

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Jul 16, 2026, 1:39 PM EDT - 17 days ago

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Arbutus initiates patent infringement actions against Pfizer, BioNTech

2026-07-16T11:45:21.000Z - 17 days ago

Arbutus initiates patent infringement actions against Pfizer, BioNTech

ABUS BNTX ROIV

Pfizer price target lowered to $30 from $34 at BMO Capital

2026-07-13T12:26:33.000Z - 20 days ago

Pfizer price target lowered to $30 from $34 at BMO Capital

Pfizer price target lowered to $35 from $36 at Guggenheim

2026-07-13T11:06:16.000Z - 20 days ago

Pfizer price target lowered to $35 from $36 at Guggenheim

Pfizer, Astellas announces FDA approval of PADCEV plus Keytruda in MIBC

2026-07-10T15:30:20.000Z - 23 days ago

Pfizer, Astellas announces FDA approval of PADCEV plus Keytruda in MIBC

MRK

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Jul 10, 2026, 11:23 AM EDT - 23 days ago

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 27 days ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

Jun 29, 2026, 4:43 PM EDT - 4 weeks ago

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

ABT ADM APD BAC CMCSA CVS DIS

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Jun 29, 2026, 1:20 AM EDT - 5 weeks ago

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 5 weeks ago

Pfizer Declares Third-Quarter 2026 Dividend

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Jun 24, 2026, 2:10 PM EDT - 5 weeks ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 5 weeks ago

Pfizer dismissed from US states' drug price-fixing lawsuit

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 12:10 PM EDT - 5 weeks ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 23, 2026, 10:00 AM EDT - 5 weeks ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:43 PM EDT - 5 weeks ago

Pfizer's experimental drug misses main goal of lung cancer trial

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 4:30 PM EDT - 5 weeks ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

Jun 22, 2026, 2:32 PM EDT - 5 weeks ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 6 weeks ago

Pfizer CFO Dave Denton to step down, leave company in August

Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 6 weeks ago

Pfizer Announces Chief Financial Officer Transition

Pfizer CEO warns German investment at risk over drug pricing policies

Jun 10, 2026, 7:56 AM EDT - 7 weeks ago

Pfizer CEO warns German investment at risk over drug pricing policies

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

Jun 9, 2026, 2:07 PM EDT - 7 weeks ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 7 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jun 9, 2026, 3:20 AM EDT - 7 weeks ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 7 weeks ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 7 weeks ago

US FDA approves Pfizer's bleeding disorder drug for children

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Jun 8, 2026, 6:45 AM EDT - 7 weeks ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Transcript: Study update

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Slides: Study update

Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Press release: Study update

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:06 AM EDT - 2 months ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 6, 2026, 9:00 AM EDT - 2 months ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 10:00 AM EDT - 2 months ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

Jun 4, 2026, 6:40 AM EDT - 2 months ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 2 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Jun 1, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 31, 2026, 8:00 AM EDT - 2 months ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30, 2026, 8:00 AM EDT - 2 months ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 29, 2026, 8:00 AM EDT - 2 months ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28, 2026, 11:10 PM EDT - 2 months ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

May 28, 2026, 7:19 PM EDT - 2 months ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 2 months ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 2 months ago

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 27, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

May 20, 2026, 9:00 AM EDT - 2 months ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20, 2026, 5:08 AM EDT - 2 months ago

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 20, 2026, 5:05 AM EDT - 2 months ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

May 18, 2026, 8:00 AM EDT - 2 months ago

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

May 14, 2026, 2:22 PM EDT - 2 months ago

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

DGX MO CL

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

May 13, 2026, 6:45 AM EDT - 2 months ago

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

May 12, 2026, 8:00 AM EDT - 2 months ago

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

ARVN RIGL

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

May 12, 2026, 7:00 AM EDT - 2 months ago

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

ARVN

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:09 PM EDT - 3 months ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

Toptradersam
Toptradersam Aug. 3 at 9:05 AM
$NBIS $BMY $PFE $NVO $ALAR 🚀 Hunting for the next big winner? Check out why this stock has my attention. Watch the full breakdown! 📈 https://www.youtube.com/watch?v=ZgFvSFCwFfE
0 · Reply
Etiqute
Etiqute Aug. 3 at 8:35 AM
$PFE 💡 Strategic TakeawayWhen higher volume drives the price upward (as seen on Friday) and lower volume occurs on down days (as seen on Wednesday), it implies institutional accumulation rather than panic selling. This dynamic is a healthy short-term sign, though Wall Street consensus remains a conservative Hold due to broader post-COVID revenue transitions and patent cliffs. High-risk single-equity exposures like this should always be positioned within a diversified portfolio to protect against sudden capital losses.
0 · Reply
Etiqute
Etiqute Aug. 3 at 8:33 AM
$PFE Volume and Price BreakdownEvaluating volume behavior alongside daily price action reveals the underlying market sentiment:Friday, July 31 (Bullish Volume): Trading volume rose to 45.08 million shares, comfortably exceeding the stock's 36.75 million average. This heavy volume accompanied a green day where the stock closed higher at $25.01, demonstrating strong buying pressure to wrap up the week.Thursday, July 30 (Bearish Volume): Volume remained high at 44.95 million shares, but the stock faced minor selling pressure, sliding slightly from its open to close at $24.91.WEDNESDAY, July 29 (Weak Bearish Volume): The stock dropped from an opening price of $25.35 to close at $25.15. Crucially, this sell-off happened on lower-than-average volume of 30.39 million shares, signaling that sellers lacked aggressive conviction.
0 · Reply
Etiqute
Etiqute Aug. 3 at 8:32 AM
$PFE Pfizer’s (PFE) stock trading volume over the last three trading days shows a moderately bullish shift in short-term volume accumulation. Despite some mixed daily price action, the volume notably expanded on days with positive price movement.
0 · Reply
Rmccall
Rmccall Aug. 3 at 4:06 AM
$PFE I own this but now loading up on $SLS diamdin in the rough
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 3 at 12:37 AM
$BMY looking great just like $PFE $GILD and of course the venerable $JNJ ⭐️ ⭐️ ⭐️ ⭐️
0 · Reply
Balancedbearizback
Balancedbearizback Aug. 2 at 11:58 PM
$PFE cancer free and rock hard
0 · Reply
CrispDry
CrispDry Aug. 2 at 10:27 PM
$ABVX just give us that $PFE or $SNY bomba tonight. I need to clear the drama and suspense
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 2 at 8:59 PM
$IGC https://youtu.be/gDDhi_U0ZWQ?is=_PgNotWj9U3p8bLY Easy money!! Why not invest and take a chance $MRNA $PFE Ram Mukunda continues to show strong, steady leadership—clear communication, disciplined execution, respected partnerships, and a sharp focus on solving major unmet needs in Alzheimer’s. Quiet confidence backed by results.
0 · Reply
reyofhope
reyofhope Aug. 2 at 8:42 PM
$PFE I believe in big Al .
0 · Reply
charleed138
charleed138 Aug. 2 at 3:37 AM
$PFE load up load up.... earning on the fourth... oil go down tech go up....
1 · Reply
JBS_84
JBS_84 Aug. 2 at 3:29 AM
$PFE And another prediction... Automated trading algorithms are going to become a problem. Are already a problem.
0 · Reply
JBS_84
JBS_84 Aug. 2 at 3:25 AM
$PFE And it already happened. Couldn't be more predictable. See you in a few days to a few weeks when Iran shoots at something
1 · Reply
drdr3
drdr3 Aug. 2 at 2:12 AM
$MCRB $PFE RHHBY $RHHBY
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 1 at 6:55 PM
Hmmm nah $PFE is not a triliion dollar company! NOT EVEN CLOSE SIR 🏦 💊 💙
1 · Reply
MrPfizer
MrPfizer Aug. 1 at 6:09 PM
$PFE this company is in great hands with Dr Bourla
0 · Reply
JBS_84
JBS_84 Aug. 1 at 5:27 PM
$PFE Prediction: By Monday trumpit will have claimed Iran was scared and capitulated. Tech bubble will go up, and oil will go down. Look throughout recent history every time Trump makes a big threat. Same playbook every time.
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 1 at 5:24 AM
$PFE buying every share i can before Bourla finally retires and the stocks goes 🚀
2 · Reply
KimberleyCarbonaro376
KimberleyCarbonaro376 Aug. 1 at 5:12 AM
$PFE Pfizer continues repositioning its business following declining COVID-related revenue. Pipeline development, strategic acquisitions, and oncology expansion remain central to its future growth strategy.
0 · Reply
Gj64
Gj64 Aug. 1 at 4:53 AM
$PFE https://www.fool.com/investing/2026/07/31/pfizer-yields-68-trades-at-85x-earnings-and-has-a/
0 · Reply
BioTechHealthX
BioTechHealthX Aug. 1 at 3:43 AM
$PFE Pfizer Inc. (NYSE: PFE) offers a long dividend history and a massive drug pipeline, but fading COVID-19 sales, patent expirations and oncology setbacks could test its 2026 turnaround. https://biotechhealthx.com/biotech-news/is-pfizer-pfe-a-smart-healthcare-stock-to-buy-now/
0 · Reply
Brice149
Brice149 Aug. 1 at 1:57 AM
$PFE I am hoping for a bump next week. I held pfizer in the past, and it was a mistake imo. But I have bought a substantial amount and sold 26 dollar calls for the end of the week. I am hoping I lose all my stock a week from today.
1 · Reply